微小残留病阴性应成为骨髓瘤治疗的终点吗？
Should minimal residual disease negativity be the end point of myeloma therapy?
作者信息
Anderson Kenneth C
机构信息
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA.
出版信息
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
Abstract
This article has a companion Counterpoint by Sonneveld. Join in the discussion of these articles at Community Conversations.
摘要
本文有一篇由索内维尔德撰写的观点相对的文章。请在“社区对话”中参与对这些文章的讨论。
相似文献
1
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应成为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
2
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应作为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
3
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
4
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.相关单倍型相合供体比匹配的无关供体是更好的选择：反对观点。
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
5
ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？观点。
Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560.
6
Related haploidentical donors are a better choice than matched unrelated donors: Point.相关的单倍体相合供体比匹配的无关供体是更好的选择：观点。
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
7
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.预防血管性血友病（VWD）相关产后出血的抗纤溶治疗：适应证与局限性
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
8
Platelets and hemostasis: a new perspective on an old subject.血小板与止血：一个古老主题的新视角。
Blood Adv. 2016 Nov 22;1(1):5-9. doi: 10.1182/bloodadvances.2016000059. eCollection 2016 Nov 29.
9
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.成人急性淋巴细胞白血病的免疫疗法：单克隆抗体的作用
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
10
Platelets as immune-sensing cells.血小板作为免疫感知细胞。
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
引用本文的文献
1
Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.扩散加权全身 MRI 在多发性骨髓瘤化疗后疗效监测中的应用：系统评价和荟萃分析。
Eur Radiol. 2022 Apr;32(4):2135-2148. doi: 10.1007/s00330-021-08311-z. Epub 2022 Jan 14.
2
Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.多参数流式细胞术用于血液系统恶性肿瘤微小残留病监测：临床应用与新挑战
Cancers (Basel). 2021 Sep 12;13(18):4582. doi: 10.3390/cancers13184582.
3
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.微小残留病阴性和来那度胺维持治疗与多发性骨髓瘤的更好生存结果相关。
Bone Marrow Transplant. 2020 Jun;55(6):1137-1146. doi: 10.1038/s41409-020-0791-y. Epub 2020 Jan 28.
4
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.多发性骨髓瘤骨髓中的微小残留病评估：对注意事项、临床意义及未来展望的综述
Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699. eCollection 2019.
5
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.流式细胞术与功能成像相结合，用于监测骨髓瘤的残留疾病。
Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20.
6
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.将免疫检查点阻断纳入嵌合抗原受体 T 细胞（CAR-T）：联合或内置 CAR-T。
Int J Mol Sci. 2018 Jan 24;19(2):340. doi: 10.3390/ijms19020340.
7
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.达雷妥尤单抗：复发和/或难治性多发性骨髓瘤的治疗药物。
Drugs. 2017 Dec;77(18):2013-2024. doi: 10.1007/s40265-017-0837-7.
本文引用的文献
1
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
2
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
3
Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.微小残留病作为潜在替代终点——尚存的问题。
JAMA Oncol. 2017 Jan 1;3(1):18-20. doi: 10.1001/jamaoncol.2016.3112.
4
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.微小残留病状态在新诊断的多发性骨髓瘤患者临床结局中的作用：一项荟萃分析。
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.
5
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
6
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
7
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.液体肿瘤的液体活检：循环游离核酸评估在血液系统恶性肿瘤管理中的新兴潜力。
Cancer Biol Med. 2016 Jun;13(2):215-25. doi: 10.20892/j.issn.2095-3941.2016.0025.
8
A new era of immune therapy in multiple myeloma.多发性骨髓瘤免疫治疗的新时代。
Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856.
9
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
10
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.美国国立综合癌症网络（NCCN）指南解读：多发性骨髓瘤，2016年第3版
J Natl Compr Canc Netw. 2016 Apr;14(4):389-400. doi: 10.6004/jnccn.2016.0046.
Zotero 插件